Discovery and targeting of a noncanonical mechanism of sarcoma resistance to ADI-PEG20 mediated by the microenvironment.

Leonard C Rogers,Jeff C Kremer,Caitlyn B Brashears,Zongtao Lin,Zhixian Hu,Alliny C S Bastos,Adriana Baker,Nicole Fettig,Dong Zhou,Kooresh I Shoghi,Carina A Dehner,John S A Chrisinger,John S Bomalaski,Benjamin A Garcia,Toshinao Oyama,Eileen P White,Brian A Van Tine

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览0

暂无评分

摘要

Noncanonical, ASS1-independent tumor resistance to ADI-PEG20 is driven by the microenvironment. This mechanism can be targeted by either the macropinocytosis inhibitor imipramine or the autophagy inhibitor chloroquine. These safe, widely available drugs should be added to current clinical trials to overcome microenvironmental arginine support of tumors and improve patient outcomes.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要